{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T01:48:10Z","timestamp":1783648090890,"version":"3.55.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T00:00:00Z","timestamp":1617753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T00:00:00Z","timestamp":1617753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Capital Clinical Characteristic Application Research Project","award":["Z151100004015206"],"award-info":[{"award-number":["Z151100004015206"]}]},{"name":"Special Fund for Military Health Committee","award":["17BJZ36"],"award-info":[{"award-number":["17BJZ36"]}]},{"name":"Special Fund for Military Health Committee","award":["18BJZ30"],"award-info":[{"award-number":["18BJZ30"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Auton Res"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Dyskinesia-hyperpyrexia syndrome (DHS) is a rare but life-threatening disease. The clinical manifestations of this syndrome overlap substantially with Parkinson hyperpyrexia syndrome and serotonin syndrome and are often confused by clinicians. The purpose of this review was to enable clinicians to recognize this syndrome and thereby reach a correct diagnosis and provide optimal treatments to improve prognosis in clinical practice.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Using the methodology described in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement, we conducted a literature search of the PubMed, Embase, and MEDLINE databases using keywords in titles and abstracts of published literature. Quality assessment was performed using the modified Newcastle-Ottawa scale.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 11 patients obtained from nine publications were included in this systematic review. All of the cases occurred in patients with advanced Parkinson's disease (PD) of long disease duration. High ambient temperature was the most common trigger of this syndrome. Hyperpyrexia and dyskinesias were present in all cases. The consciousness disturbances of this syndrome included confusion, hallucination, and lethargy or stupor. Autonomic dysfunction (except for hyperpyrexia) is uncommon in DHS, and only two patients presented with tachycardia. The treatment of this syndrome included supportive interventions (including rehydration, anti-pyretic and anti-infection treatments, and maintaining electrolyte balance), dopaminergic drug reduction and sedation. Two patients died due to DHS.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>We summarized the triggers, clinical features, and treatments of all reported dyskinesia-hyperpyrexia syndrome cases, proposed guiding diagnostic criteria, and established a flow chart to guide diagnoses to quickly identify these three syndromes in clinical practice.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10286-021-00801-w","type":"journal-article","created":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T07:03:03Z","timestamp":1617778983000},"page":"529-542","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Dyskinesia-hyperpyrexia syndrome in Parkinson\u2019s disease: a systematic review"],"prefix":"10.1007","volume":"31","author":[{"given":"Miao","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongbao","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziying","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenfu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,7]]},"reference":[{"issue":"1024","key":"801_CR1","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1136\/pgmj.2010.104976","volume":"87","author":"R Ghosh","year":"2011","unstructured":"Ghosh R, Liddle BJ (2011) Emergency presentations of Parkinson\u2019s disease: early recognition and treatment are crucial for optimum outcome. Postgrad Med J 87(1024):125\u2013131. https:\/\/doi.org\/10.1136\/pgmj.2010.104976","journal-title":"Postgrad Med J"},{"issue":"5","key":"801_CR2","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1002\/mds.1166","volume":"16","author":"PH Gordon","year":"2001","unstructured":"Gordon PH, Frucht SJ (2001) Neuroleptic malignant syndrome in advanced Parkinson\u2019s disease. Mov Disord 16(5):960\u2013962. https:\/\/doi.org\/10.1002\/mds.1166","journal-title":"Mov Disord"},{"issue":"4","key":"801_CR3","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1212\/wnl.48.4.1070","volume":"48","author":"IH Richard","year":"1997","unstructured":"Richard IH, Kurlan R, Tanner C, Factor S, Hubble J, Suchowersky O, Waters C (1997) Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson\u2019s disease. Parkinson Study Group Neurology 48(4):1070\u20131077. https:\/\/doi.org\/10.1212\/wnl.48.4.1070","journal-title":"Parkinson Study Group Neurology"},{"issue":"15","key":"801_CR4","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1002\/mds.23255","volume":"25","author":"S Gil-Navarro","year":"2010","unstructured":"Gil-Navarro S, Grandas F (2010) Dyskinesia-hyperpyrexia syndrome: another Parkinson\u2019s disease emergency. Mov Disord 25(15):2691\u20132692. https:\/\/doi.org\/10.1002\/mds.23255","journal-title":"Mov Disord"},{"issue":"2","key":"801_CR5","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1136\/bmjebm-2017-110853","volume":"23","author":"MH Murad","year":"2018","unstructured":"Murad MH, Sultan S, Haffar S, Bazerbachi F (2018) Methodological quality and synthesis of case series and case reports. BMJ Evid Based Med 23(2):60\u201363. https:\/\/doi.org\/10.1136\/bmjebm-2017-110853","journal-title":"BMJ Evid Based Med"},{"issue":"2","key":"801_CR6","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.pan.2017.02.008","volume":"17","author":"S Haffar","year":"2017","unstructured":"Haffar S, Bazerbachi F, Prokop L, Watt KD, Murad MH, Chari ST (2017) Frequency and prognosis of acute pancreatitis associated with fulminant or non-fulminant acute hepatitis A: A systematic review. Pancreatology 17(2):166\u2013175. https:\/\/doi.org\/10.1016\/j.pan.2017.02.008","journal-title":"Pancreatology"},{"key":"801_CR7","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1007\/s00415-011-6041-x","volume":"258","author":"CH Lyoo","year":"2011","unstructured":"Lyoo CH, Lee MS (2011) Rhabdomyolysis induced by severe levodopa induced dyskinesia in a patient with Parkinson\u2019s disease. J Neurol 258:1893\u20131894. https:\/\/doi.org\/10.1007\/s00415-011-6041-x","journal-title":"J Neurol"},{"key":"801_CR8","doi-asserted-by":"publisher","first-page":"182","DOI":"10.5692\/clinicalneurol.55.182","volume":"55","author":"S Taguchi","year":"2015","unstructured":"Taguchi S, Niwa J, Ibi T, Doyu M (2015) Dyskinesia-hyperpyrexia syndrome in a patient with Parkinson\u2019s disease: a case report. Rinsho Shinkeigaku 55:182\u2013184. https:\/\/doi.org\/10.5692\/clinicalneurol.55.182","journal-title":"Rinsho Shinkeigaku"},{"key":"801_CR9","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1097\/WNF.0000000000000155","volume":"39","author":"J Herreros-Rodriguez","year":"2016","unstructured":"Herreros-Rodriguez J, S\u00e1nchez-Ferro \u00c1 (2016) Summertime Dyskinesia-Hyperpyrexia Syndrome. Clin Neuropharmacol 39:210\u2013211. https:\/\/doi.org\/10.1097\/WNF.0000000000000155","journal-title":"Clin Neuropharmacol"},{"key":"801_CR10","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.parkreldis.2016.12.018","volume":"36","author":"F Acebr\u00f3n S\u00e1nchez-Herrera","year":"2017","unstructured":"Acebr\u00f3n S\u00e1nchez-Herrera F, Garc\u00eda-Barrag\u00e1n N, Est\u00e9vez-Fraga C, Mart\u00ednez-Castrillo JC, L\u00f3pez-Send\u00f3n Moreno JL (2017) Dyskinesia-hyperpyrexia syndrome under continuous dopaminergic stimulation. Parkinsonism Relat D 36:103. https:\/\/doi.org\/10.1016\/j.parkreldis.2016.12.018","journal-title":"Parkinsonism Relat D"},{"issue":"3","key":"801_CR11","doi-asserted-by":"publisher","first-page":"154","DOI":"10.14802\/jmd.17022","volume":"10","author":"MS Baek","year":"2017","unstructured":"Baek MS, Lee HW, Lyoo CH (2017) A Patient with Recurrent Dyskinesia and Hyperpyrexia Syndrome. J Mov Disord 10(3):154\u2013157. https:\/\/doi.org\/10.14802\/jmd.17022","journal-title":"J Mov Disord"},{"issue":"5","key":"801_CR12","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1002\/mdc3.12663","volume":"5","author":"M Sarchioto","year":"2018","unstructured":"Sarchioto M, Ricchi V, Melis M, Deriu M, Arca R, Melis M, Morgante F, Cossu G (2018) Dyskinesia-Hyperpyrexia Syndrome in Parkinson\u2019s Disease: A Heat Shock-Related Emergency? Mov Disord Clin Pract 5(5):534\u2013537. https:\/\/doi.org\/10.1002\/mdc3.12663","journal-title":"Mov Disord Clin Pract"},{"key":"801_CR13","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1002\/mdc3.12663","volume":"64","author":"A Novelli","year":"2019","unstructured":"Novelli A, Di Vico IA, Terenzi F, Sorbi S, Ramat S (2019) Dyskinesia-Hyperpyrexia Syndrome in Parkinson\u2019s disease with Deep Brain Stimulation and high-dose levodopa\/carbidopa and entacapone. Parkinsonism Relat D 64:352. https:\/\/doi.org\/10.1002\/mdc3.12663","journal-title":"Parkinsonism Relat D"},{"key":"801_CR14","doi-asserted-by":"publisher","unstructured":"J Zu, HK Raza, T Chansysouphanthong, C Xu, W Zhang, G Cui (2021) Dyskinesia and hyperpyrexia syndrome: A case report and review of the literature. Rev Neurol (Paris) 18; S0035\u20133787 (20) 30739\u20136. https:\/\/doi.org\/10.1016\/j.neurol.2020.10.002.","DOI":"10.1016\/j.neurol.2020.10.002"},{"key":"801_CR15","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1002\/mds.1090","volume":"16","author":"JE Ahlskog","year":"2001","unstructured":"Ahlskog JE, Muenter MD (2001) Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 16:448\u2013458. https:\/\/doi.org\/10.1002\/mds.1090","journal-title":"Mov Disord"},{"key":"801_CR16","doi-asserted-by":"publisher","first-page":"e148","DOI":"10.1212\/WNL.0000000000006737","volume":"92","author":"S Prange","year":"2019","unstructured":"Prange S, Danaila T, Laurencin C, Caire C, Metereau E, Merle H, Broussolle E, Maucort-Boulch D, Thobois S (2019) Age and time course of long-term motor and nonmotor complications in Parkinson disease. Neurology 92:e148\u2013e160. https:\/\/doi.org\/10.1212\/WNL.0000000000006737","journal-title":"Neurology"},{"issue":"1","key":"801_CR17","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1212\/wnl.53.1.91","volume":"53","author":"PJ Blanchet","year":"1999","unstructured":"Blanchet PJ, Fang J, Hyland K, Arnold LA, Mouradian MM, Chase TN (1999) Short-term effects of high-dose 17beta-estradiol in postmenopausal PD patients: a crossover study. Neurology 53(1):91\u201395. https:\/\/doi.org\/10.1212\/wnl.53.1.91","journal-title":"Neurology"},{"issue":"2","key":"801_CR18","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1097\/00002826-200203000-00004","volume":"25","author":"M Zappia","year":"2002","unstructured":"Zappia M, Crescibene L, Arabia G, Nicoletti G, Bagala A, Bastone L, Caracciolo M, Bonavita S, Di Costanzo A, Scornaienchi M, Gambardella A, Quattrone A (2002) Body weight influences pharmacokinetics of levodopa in Parkinson\u2019s disease. Clin Neuropharmacol 25(2):79\u201382. https:\/\/doi.org\/10.1097\/00002826-200203000-00004","journal-title":"Clin Neuropharmacol"},{"issue":"3","key":"801_CR19","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s10072-011-0842-7","volume":"33","author":"S Yamashita","year":"2012","unstructured":"Yamashita S, Uchida Y, Kojima S, Sakaguchi H, Kimura E, Maeda Y, Uchino M (2012) Heatstroke in patients with Parkinson\u2019s disease. Neurol Sci 33(3):685\u2013687. https:\/\/doi.org\/10.1007\/s10072-011-0842-7","journal-title":"Neurol Sci"},{"issue":"5","key":"801_CR20","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1007\/BF00169004","volume":"346","author":"MT Lin","year":"1992","unstructured":"Lin MT, Ho MT, Young MS (1992) Stimulation of the nigrostriatal dopamine system inhibits both heat production and heat loss mechanisms in rats. Naunyn Schmiedebergs Arch Pharmacol 346(5):504\u2013510. https:\/\/doi.org\/10.1007\/BF00169004","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"5","key":"801_CR21","doi-asserted-by":"publisher","first-page":"R471","DOI":"10.1152\/ajpregu.1982.242.5.R471","volume":"242","author":"MT Lin","year":"1982","unstructured":"Lin MT, Chandra A, Tsay BL, Chern YF (1982) Hypothalamic and striatal dopamine receptor activation inhibits heat production in the rat. Am J Physiol 242(5):R471-481. https:\/\/doi.org\/10.1152\/ajpregu.1982.242.5.R471","journal-title":"Am J Physiol"},{"issue":"1","key":"801_CR22","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1001\/archneur.64.1.141","volume":"64","author":"R de la Fuente-Fern\u00e1ndez","year":"2007","unstructured":"de la Fuente-Fern\u00e1ndez R (2007) Presynaptic mechanisms of motor complications in Parkinson disease. Arch Neurol 64(1):141\u2013143. https:\/\/doi.org\/10.1001\/archneur.64.1.141","journal-title":"Arch Neurol"},{"issue":"1","key":"801_CR23","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1001\/archneur.64.1.137","volume":"64","author":"G Linazasoro","year":"2007","unstructured":"Linazasoro G (2007) Pathophysiology of motor complications in Parkinson disease: postsynaptic mechanisms are crucial. Arch Neurol 64(1):137\u2013140. https:\/\/doi.org\/10.1001\/archneur.64.1.137","journal-title":"Arch Neurol"},{"issue":"2\u20133","key":"801_CR24","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/s0304-3940(97)00958-0","volume":"241","author":"F Canini","year":"1998","unstructured":"Canini F, Bourdon L (1998) Dopamine involvement in thermoregulatory responses to heat in rats. Neurosci Lett 241(2\u20133):91\u201394. https:\/\/doi.org\/10.1016\/s0304-3940(97)00958-0","journal-title":"Neurosci Lett"},{"issue":"5","key":"801_CR25","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1152\/jn.00066.2005","volume":"94","author":"E Guatteo","year":"2005","unstructured":"Guatteo E, Chung KKH, Bowala TK, Bernardi G, Mercuri NB, Lipski J (2005) Temperature sensitivity of dopaminergic neurons of the substantia nigra pars compacta: involvement of transient receptor potential channels. J Neurophysiol 94(5):3069\u20133080. https:\/\/doi.org\/10.1152\/jn.00066.2005","journal-title":"J Neurophysiol"},{"issue":"1","key":"801_CR26","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.pnpbp.2010.09.014","volume":"35","author":"H-Y Tsai","year":"2011","unstructured":"Tsai H-Y, Chen KC, Yang YK, Chen PS, Yeh TL, Chiu NT, Hui Lee I (2011) Sunshine-exposure variation of human striatal dopamine D2\/D3 receptor availability in healthy volunteers. Prog Neuropsychopharmacol Biol Psychiatry 35(1):107\u2013110. https:\/\/doi.org\/10.1016\/j.pnpbp.2010.09.014","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"3","key":"801_CR27","doi-asserted-by":"publisher","first-page":"e1076","DOI":"10.1038\/tp.2017.18","volume":"7","author":"JR Petrulli","year":"2017","unstructured":"Petrulli JR, Kalish B, Nabulsi NB, Huang Y, Hannestad J, Morris ED (2017) Systemic inflammation enhances stimulant-induced striatal dopamine elevation. Transl Psychiatry 7(3):e1076. https:\/\/doi.org\/10.1038\/tp.2017.18","journal-title":"Transl Psychiatry"},{"issue":"5","key":"801_CR28","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1097\/00005053-198105000-00011","volume":"169","author":"M Toru","year":"1981","unstructured":"Toru M, Matsuda O, Makiguchi K, Sugano K (1981) Neuroleptic malignant syndrome-like state following a withdrawal of antiparkinsonian drugs. J Nerv Ment Dis 169(5):324\u2013327. https:\/\/doi.org\/10.1097\/00005053-198105000-00011","journal-title":"J Nerv Ment Dis"},{"issue":"Suppl 1","key":"801_CR29","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1016\/s1353-8020(02)00124-4","volume":"9","author":"T Harada","year":"2003","unstructured":"Harada T, Mitsuoka K, Kumagai R, Murata Y, Kaseda Y, Kamei H, Ishizaki F, Nakamura S (2003) Clinical features of malignant syndrome in Parkinson\u2019s disease and related neurological disorders. Parkinsonism Relat Disord 9(Suppl 1):S15-23. https:\/\/doi.org\/10.1016\/s1353-8020(02)00124-4","journal-title":"Parkinsonism Relat Disord"},{"issue":"9","key":"801_CR30","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1007\/s00415-005-0798-8","volume":"252","author":"C Gaig","year":"2005","unstructured":"Gaig C, Marti MJ, Tolosa E, Gomez-Choco MJ, Amaro S (2005) Parkinsonism-hyperpyrexia syndrome not related to antiparkinsonian treatment withdrawal during the 2003 summer heat wave. J Neurol 252(9):1116\u20131119. https:\/\/doi.org\/10.1007\/s00415-005-0798-8","journal-title":"J Neurol"},{"issue":"5","key":"801_CR31","doi-asserted-by":"publisher","first-page":"e229122","DOI":"10.1136\/bcr-2018-229122","volume":"12","author":"J Azar","year":"2019","unstructured":"Azar J, Elinav H, Safadi R, Soliman M (2019) Malignant deep brain stimulator withdrawal syndrome. BMJ Case Rep 12(5):e229122. https:\/\/doi.org\/10.1136\/bcr-2018-229122","journal-title":"BMJ Case Rep"},{"issue":"Suppl 1","key":"801_CR32","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1016\/s1353-8020(02)00122-0","volume":"9","author":"H Takubo","year":"2003","unstructured":"Takubo H, Harada T, Hashimoto T, Inaba Y, Kanazawa I, Kuno S, Mizuno Y, Mizuta E, Murata M, Nagatsu T, Nakamura S, Yanagisawa N, Narabayashi H (2003) A collaborative study on the malignant syndrome in Parkinson\u2019s disease and related disorders. Parkinsonism Relat Disord 9(Suppl 1):S31-41. https:\/\/doi.org\/10.1016\/s1353-8020(02)00122-0","journal-title":"Parkinsonism Relat Disord"},{"issue":"11","key":"801_CR33","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1056\/NEJMra041867","volume":"352","author":"EW Boyer","year":"2005","unstructured":"Boyer EW, Shannon M (2005) The serotonin syndrome. N Engl J Med 352(11):1112\u20131120. https:\/\/doi.org\/10.1056\/NEJMra041867","journal-title":"N Engl J Med"},{"issue":"3","key":"801_CR34","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1081\/clt-120037428","volume":"42","author":"GK Isbister","year":"2004","unstructured":"Isbister GK, Bowe SJ, Dawson A, Whyte IM (2004) Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. J Toxicol Clin Toxicol 42(3):277. https:\/\/doi.org\/10.1081\/clt-120037428","journal-title":"J Toxicol Clin Toxicol"},{"issue":"9","key":"801_CR35","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1093\/qjmed\/hcg109","volume":"96","author":"EJ Dunkley","year":"2003","unstructured":"Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM (2003) The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM 96(9):635\u2013642. https:\/\/doi.org\/10.1093\/qjmed\/hcg109","journal-title":"QJM"}],"container-title":["Clinical Autonomic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10286-021-00801-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10286-021-00801-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10286-021-00801-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T16:20:42Z","timestamp":1626798042000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10286-021-00801-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,7]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["801"],"URL":"https:\/\/doi.org\/10.1007\/s10286-021-00801-w","relation":{},"ISSN":["0959-9851","1619-1560"],"issn-type":[{"value":"0959-9851","type":"print"},{"value":"1619-1560","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,7]]},"assertion":[{"value":"17 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}